Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty

OBJECTIVE—Lefradafiban is the orally active prodrug of fradafiban, a glycoprotein IIb/IIIa receptor antagonist. The present phase II study aimed to determine the dose of lefradafiban that provides 80% blockade of the glycoprotein IIb/IIIa receptors by fradafiban, and to study the pharmacodynamics an...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Akkerhuis, K, van den Brand, M J B M, van der Zwaan, C, Peels, H, Suryapranata, H, van der Wieken, L R, Stibbe, J, Hoffmann, J, Baardman, T, Deckers, J, Simoons, M
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2001
Pynciau:
Interventional Cardiology Surgery
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC1729676/
https://ncbi.nlm.nih.gov/pubmed/11250974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/heart.85.4.444
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg